Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 with enfortumab vedotin with or without pembrolizumab in locally advanced or metastatic urothelial carcinoma
NL-OMON59950Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan, enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC), sponsored by Merck & Co. Primary endpoint: Percentage of participants with dose-limiting toxicities. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59950.